The genetic bases of uterine fibroids; a review

Journal of Reproduction and Infertility

Volumn 12, Issue 3, 2011, Pages 181-191

  Medikare, Veronica ^a   Kandukuri, Lakshmi Rao ^b   Ananthapur, Venkateshwari ^c   Deenadayal, Mamata ^d   Nallari, Pratibha ^a  

^a OSMANIA UNIVERSITY   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^c OSMANIA UNIVERSITY   (India)

^d Infertility Institute and Research Centre   (India)

Author keywords

Chromosomal; Chromosomal translocation; Estrogen; Gene rearrangement; Progesterone; Uterine fibroids; Uterine leiomyomas (UL)

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; HIGH MOBILITY GROUP A PROTEIN; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN PCOLCE; RAD51 PROTEIN; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ALU SEQUENCE; CELL GROWTH; CHROMOSOME 12; CHROMOSOME 12Q; CHROMOSOME 14; CHROMOSOME 6; CHROMOSOME 6P; CHROMOSOME 7; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 14; CYTOGENETICS; FEMALE; GENE DISRUPTION; GENE EXPRESSION; HEREDITY; HUMAN; KARYOTYPE; PATHOGENESIS; REVIEW; RISK FACTOR; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR GROWTH; UTERUS MYOMA; X CHROMOSOME INACTIVATION;

EID: 80054899008     PISSN: 22285482     EISSN: 2251676X     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Center for Uterine Fibroids [Internet]. Boston: Brigham and Women's Hospital; 2011. What are fibroids?; 2006 Sept 19 [cited 2011 Mar 13]; [about 3 screens]. Available from: http://www.fibroids. net/aboutfibroids.html
2. Nivethithai P, Nikhat SR, Rajesh BV. Uterine Fibroids: A Review. Indian J Pharm Pract. 2010;3 (1):6-11.
3. Blake RE. Leiomyomata uteri: hormonal and molecular determinants of growth. J Natl Med Assoc. 2007;99(10):1170-84. (Pubitemid 47614589)
4. Luo X, Chegini N. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med. 2008;26 (6):500-14.
5. Zavadil J, Ye H, Liu Z, Wu J, Lee P, Hernando E, et al. Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One. 2010;5(8):e12362.
6. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet. 2005;158(1): 1-26. (Pubitemid 40354320)
7. Cramer SF, Horiszny JA, Leppert P. Epidemiology of uterine leiomyomas. With an etiologic hypothesis. J Reprod Med. 1995;40(8):595-600.
8. Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol. 1988;72(6):853-7.
9. Samadi AR, Lee NC, Flanders WD, Boring JR 3rd, Parris EB. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health. 1996;86(6):858-62. (Pubitemid 26192026)
10. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70(3):432-9. (Pubitemid 28435626)
11. Zaitseva M, Vollenhoven BJ, Rogers PA. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol Hum Reprod. 2006;12(3):187-207.
12. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-73. (Pubitemid 27510139)
13. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003;111(8):1037-54. (Pubitemid 36826884)
14. Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based casecontrol study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol. 2001;153(1):11-9. (Pubitemid 32041891)
15. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect. 2000;108 Suppl 5:791-3.
16. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4): 725-36. (Pubitemid 46553757)
17. Romieu I, Walker AM, Jick S. Determinants of uterine fibroids. Post Marketing Surveill. 1991;5: 119-33.
18. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293(6543):359-62. (Pubitemid 16034122)
19. Friedman AJ, Harrison-Atlas D, Barbieri RL, Benacerraf B, Gleason R, Schiff I. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989;51(2):251-6. (Pubitemid 19050523)
20. Mashal RD, Fejzo ML, Friedman AJ, Mitchner N, Nowak RA, Rein MS, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer. 1994;11(1):1-6. (Pubitemid 24273967)
21. GLOWM: The Global Library of Women's Medicine [Internet]. London: The Foundation for The Global Library of Women's Medicine; 2010. Genetics of uterine leiomyomas; 2009 May [cited Mar 13]. Available from: http://www.glowm. com/?p=glowm.cml/section-view&articleid=363
22. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2000;121(1):1-8. (Pubitemid 30665733)
23. Packenham JP, du Manoir S, Schrock E, Risinger JI, Dixon D, Denz DN, et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog. 1997;19(4):273-9. (Pubitemid 27392007)
24. Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet. 2007;16 Spec No 1:R7-13.
25. Nibert M, Heim S. Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer. 1990;2(1):3- 13.
26. El-Gharib MN, Elsobky ES. Cytogenetic aberrations and the development of uterine leiomyomata. J Obstet Gynaecol Res. 2010;36(1):101-7.
27. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7(12):899-910. (Pubitemid 350165857)
28. Kazmierczak B, Pohnke Y, Bullerdiek J. Fusion transcripts between the HMGIC gene and RTVLH- related sequences in mesenchymal tumors without cytogenetic aberrations. Genomics. 1996; 38(2):223-6. (Pubitemid 26424602)
29. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell. 1995;82(1):57- 65.
30. Schoenmakers EF, Van de Ven WJ. From chromosome aberrations to the high mobility group protein gene family: evidence for a common genetic denominator in benign solid tumor development. Cancer Genet Cytogenet. 1997;95(1):51-8. (Pubitemid 27188447)
31. Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Faa G, Pauwels P, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest. 2000; 80(3):359-69. (Pubitemid 30167795)
32. Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, et al. HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer. 2003;38(1): 68-79. (Pubitemid 36994885)
33. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, et al. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res. 2003;63(6):1351-8. (Pubitemid 36348716)
34. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008;6(4):663-73. (Pubitemid 351521848)
35. Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer. 2007;46(4):336-47. (Pubitemid 46411325)
36. Kazmierczak B, Bol S, Wanschura S, Bartnitzke S, Bullerdiek J. PAC clone containing the HMGI(Y) gene spans the breakpoint of a 6p21 translocation in a uterine leiomyoma cell line. Genes Chromosomes Cancer. 1996;17(3):191-3. (Pubitemid 26418698)
37. Dal Cin P, Wanschura S, Christiaens MR, Van den Berghe I, Moerman P, Polito P, et al. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer. 1997;20(1):90-2. (Pubitemid 27377104)
38. Williams AJ, Powell WL, Collins T, Morton CC. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol. 1997;150(3):911-8. (Pubitemid 27106163)
39. Xiao S, Lux ML, Reeves R, Hudson TJ, Fletcher JA. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol. 1997; 150(3):901-10. (Pubitemid 27106162)
40. Schoenmakers EF, Huysmans C, Van de Ven WJ. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res. 1999;59(1):19- 23.
41. Ingraham SE, Lynch RA, Kathiresan S, Buckler AJ, Menon AG. hREC2, a RAD51-like gene, is disrupted by t(12;14) (q15;q24.1) in a uterine leiomyoma. Cancer Genet Cytogenet. 1999;115(1): 56-61. (Pubitemid 29505220)
42. Takahara K, Kessler E, Biniaminov L, Brusel M, Eddy RL, Jani-Sait S, et al. Type I procollagen COOH-terminal proteinase enhancer protein: identification, primary structure, and chromosomal localization of the cognate human gene (PCOL CE). J Biol Chem. 1994;269(42):26280-5. (Pubitemid 24328445)
43. Xing YP, Powell WL, Morton CC. The del(7q) subgroup in uterine leiomyomata: genetic and biologic characteristics. Further evidence for the secondary nature of cytogenetic abnormalities in the pathobiology of uterine leiomyomata. Cancer Genet Cytogenet. 1997;98(1):69-74.
44. Scott IC, Clark TG, Takahara K, Hoffman GG, Greenspan DS. Structural organization and expression patterns of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. Genomics. 1999;55(2):229-34. (Pubitemid 29093518)
45. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996;2(4): 295- 306.